このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Genmab マネジメント

マネジメント基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Jan G.J. de Winkel

最高経営責任者

kr.44.3m

報酬総額

CEO給与比率	20.8%
CEO在任期間	14yrs
CEOの所有権	0.9%
経営陣の平均在職期間	7yrs
取締役会の平均在任期間	7.3yrs

経営陣の近況

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Mar 07

Recent updates

Genmab A/S' (CPH:GMAB) Price In Tune With Earnings

Apr 02

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Mar 07

CEO報酬分析

Genmab の収益と比較して、Jan G.J. de Winkel の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	kr.5b
Dec 31 2023	kr.44m	kr.9m	kr.4b
Sep 30 2023	n/a	n/a	kr.4b
Jun 30 2023	n/a	n/a	kr.5b
Mar 31 2023	n/a	n/a	kr.5b
Dec 31 2022	kr.42m	kr.9m	kr.5b
Sep 30 2022	n/a	n/a	kr.6b
Jun 30 2022	n/a	n/a	kr.4b
Mar 31 2022	n/a	n/a	kr.2b
Dec 31 2021	kr.38m	kr.8m	kr.3b
Sep 30 2021	n/a	n/a	kr.3b
Jun 30 2021	n/a	n/a	kr.3b
Mar 31 2021	n/a	n/a	kr.6b
Dec 31 2020	kr.37m	kr.7m	kr.5b
Sep 30 2020	n/a	n/a	kr.6b
Jun 30 2020	n/a	n/a	kr.6b
Mar 31 2020	n/a	n/a	kr.2b
Dec 31 2019	kr.35m	kr.7m	kr.2b
Sep 30 2019	n/a	n/a	kr.2b
Jun 30 2019	n/a	n/a	kr.1b
Mar 31 2019	n/a	n/a	kr.1b
Dec 31 2018	kr.28m	kr.7m	kr.1b
Sep 30 2018	n/a	n/a	kr.1b
Jun 30 2018	n/a	n/a	kr.1b
Mar 31 2018	n/a	n/a	kr.1b
Dec 31 2017	kr.27m	kr.7m	kr.1b

報酬と市場: Jan G.J.の総報酬 ($USD 6.38M ) は、 Danish市場 ($USD 4.19M ) の同規模の企業の平均を上回っています。

報酬と収益: Jan G.J.の報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Jan G.J. de Winkel (63 yo)

14yrs

在職期間

kr.44,300,000

報酬

Dr. Jan G.J. van de Winkel, Ph.D. is Independent Director of HOOKIPA Pharma Inc. from 2023 and serves as Chairman of the Board since 2024. Dr. Winkel served as a Member of Advisory board at Thuja Capital M...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jan G.J. de Winkel	Co-Founder	14yrs	kr.44.30m	0.95% DKK 1.1b
Anthony Pagano	Executive VP & CFO	4.3yrs	kr.19.60m	0.011% DKK 12.6m
Anthony Mancini	Executive VP & COO	4.3yrs	kr.21.80m	0.0045% DKK 5.2m
Birgitte Stephensen	Executive VP & Chief Legal Officer	14.4yrs	kr.10.10m	データなし
Christopher Cozic	Executive VP & Chief People Officer	6.6yrs	kr.13.20m	データなし
Martine van Vugt	Executive VP & Chief Strategy Officer	10.4yrs	kr.8.90m	データなし
Martin Schultz	Senior Director of Clinical Operations & Non-Independent Director	no data	kr.800.00k	0.00060% DKK 693.1k
Judith Klimovsky	Executive VP & Chief Development Officer	7.3yrs	kr.21.70m	0.014% DKK 15.8m
Tahamtan Ahmadi	Executive VP	3.3yrs	kr.19.80m	0.0048% DKK 5.6m
Mijke Zachariasse	Senior Director	no data	kr.1.10m	0.00082% DKK 947.3k
Takahiro Hamatani	Senior Director of Finance Japan & Non-Independent Director	no data	kr.800.00k	0.00013% DKK 150.2k
Andrew Carlsen	Senior Director	no data	データなし	データなし

7.0yrs

平均在職期間

51yo

平均年齢

経験豊富な経営陣: GMABの経営陣は経験豊富で経験豊富です（平均在職期間は7.3年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Martin Schultz	Senior Director of Clinical Operations & Non-Independent Director	2.4yrs	kr.800.00k	0.00060% DKK 693.1k
Mijke Zachariasse	Senior Director	5.3yrs	kr.1.10m	0.00082% DKK 947.3k
Takahiro Hamatani	Senior Director of Finance Japan & Non-Independent Director	2.4yrs	kr.800.00k	0.00013% DKK 150.2k
Anders Pedersen	Non-Independent Director	20.6yrs	kr.1.70m	0.011% DKK 13.2m
Elizabeth O'Farrell	Independent Director	2.3yrs	kr.1.90m	データなし
Deirdre Connelly	Independent Chairman of the Board	7.3yrs	kr.2.80m	0.0090% DKK 10.4m
Rolf Hoffmann	Independent Director	7.3yrs	kr.1.50m	0.0053% DKK 6.1m
Pernille Erenbjerg	Independent Deputy Chairman	9.4yrs	kr.2.10m	0.0076% DKK 8.8m
Paolo Paoletti	Independent Director	9.4yrs	kr.1.50m	0.0033% DKK 3.8m

7.3yrs

平均在職期間

59yo

平均年齢

経験豊富なボード: GMABの取締役会は経験豊富であると考えられます ( 7.3年の平均在任期間)。

Genmab マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Non-Independent Director recently sold kr.3.8m worth of stock

Genmab A/S Announces Executive Changes

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Executive VP & CFO recently sold kr.22m worth of stock

Executive VP & CFO exercised options to buy kr.22m worth of stock.

Genmab A/S, Annual General Meeting, Mar 13, 2024

Recent updates

Non-Independent Director recently sold kr.3.8m worth of stock

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Consensus EPS estimates fall by 11%

First quarter 2024 earnings released: EPS: kr.20.29 (vs kr.3.46 in 1Q 2023)

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S' (CPH:GMAB) Price In Tune With Earnings

Genmab A/S Announces Executive Changes

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Executive VP & CFO recently sold kr.22m worth of stock

Executive VP & CFO exercised options to buy kr.22m worth of stock.

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab's (CPH:GMAB) Conservative Accounting Might Explain Soft Earnings

Full year 2023 earnings: EPS misses analyst expectations

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Is Genmab A/S (CPH:GMAB) Trading At A 50% Discount?

Genmab A/S Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: kr.32.60 (vs kr.39.55 in 3Q 2022)

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Investor sentiment deteriorates as stock falls 16%

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Is Now The Time To Put Genmab (CPH:GMAB) On Your Watchlist?

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

Co-Founder recently sold kr.58m worth of stock

Is There An Opportunity With Genmab A/S' (CPH:GMAB) 44% Undervaluation?

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

First quarter 2023 earnings released: EPS: kr.3.46 (vs kr.7.10 in 1Q 2022)

Independent Chairman of the Board recently bought kr.796k worth of stock

With EPS Growth And More, Genmab (CPH:GMAB) Makes An Interesting Case

Genmab A/S (CPH:GMAB) Shares Could Be 50% Below Their Intrinsic Value Estimate

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Here's Why We Think Genmab (CPH:GMAB) Is Well Worth Watching

Co-Founder recently sold kr.57m worth of stock

Genmab A/S Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Are Investors Undervaluing Genmab A/S (CPH:GMAB) By 46%?

Genmab A/S Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (Bla) for Epcoritamab (Duobody®-Cd3xcd20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (Lbcl)

Consensus EPS estimates increase by 45%

Third quarter 2022 earnings released: EPS: kr.39.55 (vs kr.13.61 in 3Q 2021)

Genmab Provides Earnings Guidance for Year 2022

Genmab A/S Submits Biologics License Application to the U.S. Food and Drug Administration

Do Genmab's (CPH:GMAB) Earnings Warrant Your Attention?

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

マネジメント基準チェック /34